Navigation Links
The Connection Between Vitamin E and Patients with Diabetes and Nonalcoholic Steatohepatitis
Date:11/17/2015

SAN FRANCISCO, Nov. 17, 2015 /PRNewswire/ -- There have been numerous studies on the safety and efficacy of using vitamin E to treat nondiabetic patients with nonalcoholic steatohepatitis (NASH), but researchers at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) presented results of vitamin E in diabetic and nondiabetic patients.

According to the study's principal investigator Kris Kowdley, MD, FAASLD, Director of the Liver Care Network and Organ Care Research at Swedish Medical Center, in Seattle, Washington, USA this is the first time data on diabetic patients with NASH is being presented, and the results show that vitamin E shows the same efficacy in patients with diabetes as in those without diabetes.

NASH is a metabolic disorder that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol and can occur in children to the elderly, as well as people with and without diabetes.  Vitamin E has been studied as a treatment for NASH in the PIVENS trial which included subjects without diabetes. The investigators previously showed that vitamin E showed histologic improvement non-diabetic patients with NASH.

The FLINT trial of obeticholic acid versus placebo allowed patients with diabetes to be enrolled; the trial was stopped early because it met its primary endpoint and demonstrated significant histologic improvement with obeticholic acid. Concomitant vitamin E use was permitted in study subjects in the FLINT study.

In the study presented at this meeting, researchers looked at histologic improvement and NASH resolution among the PIVENS and placebo-treated FLINT patients with and without diabetes taking vitamin E. They also looked at the incidence of cardiac events and changes in serum lipid levels. Data were examined from 250 total patients randomized to vitamin E (80 subjects) in PIVENS, placebo in PIVENS (72 subjects) and FLINT patients being treated with placebo (98 subjects) including patients taking and not taking vitamin E.

The results of the pooled analysis from these studies demonstrate that safety and efficacy of vitamin E is the same for patients with NASH and diabetes as for those with NASH and without diabetes. As many patients with NASH also have diabetes, the authors of their findings support clinical trials in diabetic NASH.

"This study provides evidence supporting further study of vitamin E in both diabetic and non-diabetic patients with NASH; vitamin E use was not associated with increased cardiac complications or altered serum lipid levels in diabetic patients," said Dr. Kowdley.

Abstract title: Efficacy and safety of vitamin E in nonalcoholic steatohepatitis patients with and without diabetes: Pooled analysis from the PIVENS and FLINT NIDDK NASH CRN trials

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, CA, November 14-17, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 13 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766
gbologna@aasld.org
Press Room: November 13 – 17, 2015
Moscone West Convention Center, San Francisco, CA
Telephone: 415-348-4404

Researcher: Kris V. Kowdley, MD
Email: Kris.Kowdley@swedish.org
Phone: 206-459-8479 

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
2. MedConnections Released PACE Health Connect App To Allow Patients To Manage Health Care Faster And Easier
3. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
4. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
5. B. Riley Exclusive Financial Advisor to Mirth Corporation in Connection with its Corporate Sale to Quality Systems, Inc.
6. The Diabetes and Sleep Apnea Connection
7. Transvaginal Mesh Surgery and Organ Perforation: The Dangerous Connection
8. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
9. MBA students eye Rutgers Business Schools biopharmaceutical case competition as a chance to demonstrate their knowledge of the pharmaceutical business and make valuable connections.
10. Novation Among Leaders Developing New Standards to Prevent Tubing Misconnections
11. Endo Announces Early Termination of HSR Act Waiting Period and Canadian Competition Act Compliance in Connection with Its Proposed Acquisition of Paladin Labs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Arc ... developmental disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people with special ... first organization of its kind in the state of New Jersey – but the ...
(Date:8/23/2017)... ... August 23, 2017 , ... Loyale Healthcare ... Sector Growth. Mr. Smith joins other recent high-profile hires including Frank Massi, Chief ... career began in 1993, helping physician practices and hospitals automate their clinical and ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research and ... of HBOT in treating and helping to heal addictions and substance abuse disorders. ... similarities of the wounds to the brain from traumatic brain injuries, and the ...
(Date:8/23/2017)... ... ... Nightingale College continues the semiannual Give Back Day tradition for its fourth ... to serving and volunteering for organizations that provide indispensable resources to the community. The ... a little extra help. , The College’s Give Back Day initiative began in ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the top 20% of hospitals nationally that earned the designation of High Performing ... overall rating of high performing indicates a hospital was significantly better than the ...
Breaking Medicine News(10 mins):